NEW YORK, Dec. 15 /PRNewswire/ -- Advanced BioHealing, Inc. (ABH) today presented results of a long term product stability study of Celaderm(TM), the Company's next generation bioengineered tissue product. The findings were presented at the 4th Annual Commercialisation of Tissue Engineering & Cell Therapy meeting in London, U.K.
